On Friday, Invivyd Inc. IVVD introduced that new in vitro neutralization information present continued neutralizing exercise of Pemgarda (pemivibart) and pipeline candidate VYD2311 in opposition to dominant SARS-CoV-2 variant XEC.
The inventory is buying and selling with a robust session quantity of 12.3 million, in comparison with a mean quantity of 757.02k as per information from Benzinga Professional.
As anticipated, the information are largely in step with these beforehand reported for KP.3.1.1, primarily based on the structural biology of pemivibart and VYD2311.
The Facilities for Illness Management (CDC) estimates that XEC and KP.3.1.1 accounted for an combination 69% of U.S. circulating variants of SARS-CoV-2 for the 2 weeks ended December 21, 2024.
Invivyd generated these new information as a part of its ongoing industrial virology effort. It leverages a third-party pseudoviral system that routinely assessments genuine Invivyd-produced pemivibart and is supported by intensive structure-based and proprietary analytics.
Invivyd has confirmed constructive Pemgarda neutralization exercise in opposition to over 75% of at present circulating U.S. variants and all prior variants examined to this point.
Additional, the corporate estimates that each scientific variant reported within the CDC COVID Tracker for the reason that Omicron BA.1 lineage has been inclined to pemivibart, even when untested, as a result of constant structural integrity of the pemivibart epitope.
Due to this fact, Invivyd doesn’t anticipate any significant change to pemivibart neutralization exercise, other than anticipated regular quantitative variation in assay output, for the foreseeable future if the epitope pemivibart targets stay structurally intact, because it has since Omicron BA.1.
In November, Invivyd introduced {that a} manuscript preprint conveying information from the CANOPY Section 3 scientific trial of pemivibart for the pre-exposure prophylaxis of COVID-19, together with long-term safety proven versus latest JN.1 sublineages at low residual titers, was uploaded to MedRxiv.
Value Motion: IVVD inventory is down 5.5% at $0.4357 finally verify Friday.
Learn Subsequent:
Picture by way of Shutterstock.
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
